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Highlights:  
 Clinical and prognostic role of pro-enkephalin has tested in chronic and acute heart 
failure. 
 Pro-enkephalin was correlated with glomerular function but not with tubular 
dysfunction. 
 Pro-enkephalin did not show an additive prognostic information on top of preexisting 
renal markers in acute heart failure.  
 
Abstract 
Background 
Proenkephalin (pro-ENK) has emerged as a novel biomarker associated with both renal function 
and cardiac function. However, its clinical and prognostic value have not been well evaluated in 
symptomatic patients with heart failure.  
Methods and Results 
The association between pro-ENK and markers of renal function was evaluated in 95 patients 
with chronic heart failure who underwent renal hemodynamic measurements including renal 
blood flow (RBF) and glomerular filtration rate (GFR) using131I-Hippuran and 125I-Iothalamate 
clearances, respectively. The association between pro-ENK and clinical outcome in acute heart 
failure was assessed in another 1589 patients. Pro-ENK was strongly correlated with both RBF 
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(P<0.001) and GFR (P<0.001), but not with renal tubular markers. In the acute heart failure 
cohort, pro-ENK was a predictor of death through 180 days, heart failure rehospitalization 
through 60 days, and death or cardiovascular or renal rehospitalization through day 60 in 
univariable analyses, but its predictive value was lost in a multivariable model, when other renal 
markers were entered in the model.  
Conclusions  
In patients with chronic and acute heart failure, pro-ENK is strongly associated with glomerular 
function, but not with tubular damage. Pro-ENK provides limited prognostic information in 
patients with acute heart failure on top of established renal markers.  
 
Keywords: renal function; heart failure; prognosis; enkephalin 
 
Introduction 
Renal dysfunction is frequently observed in patients with heart failure1, and both baseline renal 
function and worsening of renal function accompanying inadequate decongestion during 
hospitalization is associated with prolonged hospitalization, rehospitalization, and death2, 3.  
Enkephalins including pro-enkephalin (pro-ENK) are small endogenous opioid peptides 
encoded by the proenkephalin gene, and have been shown to be implicated in 
neurotransmission, autocrine and paracrine function, and cardiac function. Most of the early 
studies have focused on its role in neuronal tissues, but it is also suggested to be produced and 
act in non-neural tissues including heart and kidney4. Due to the instability of enkephalins, a 
stable fragment of their precursor, termed pro-ENK, has been devised as stable and reliable 
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surrogate plasma marker5. In patients with acute kidney injury after cardiac surgery, pro-ENK 
was shown to rapidly increase6. In acute myocardial infarction, increased pro-ENK was 
associated with renal dysfunction and predicted major cardiac events7. These results suggest a 
potential of pro-ENK as a novel cardiorenal biomarker, although its role in chronic and acute 
heart failure has not been established. Here, we evaluate the association between pro-ENK and 
indices of glomerular and tubular function and clinical outcome in patients with acute and 
chronic heart failure. 
 
Methods 
This study was performed in two populations. First, a cardiorenal mechanistic cohort was used 
to investigate the association between pro-ENK and renal function including hemodynamic 
parameters which were measured by radioactive tracers in  patients with stable chronic heart 
failure8, 9. Second, the PROTECT (Placebo-controlled Randomized study of the selective A1 
adenosine receptor antagonist rolofylline for the patients hospitalized with acute heart failure 
and volume Overload to assess Treatment Effect on Congestion and renal functTion) study 
cohort (acute heart failure cohort) was used to study the association between pro-ENK and 
prognosis in patients with acute heart failure10. Measurement of pro-ENK was performed using a 
sandwich immunoassay with antibodies against the proenkephalin A 119-159 peptide by 
Sphingotec inc.5, 7. The lower detection limit was 5.5 pmol/L. Intra- and inter-assay coefficients 
of variation were 6.4 and 9.5% at 50 pmol/L, and 4.0 and 6.5% at 150 pmol/L, respectively. The 
normal value of pro-ENK was measured in a general population, and determined as 46.6 ±14.1 
pmol/L and median value of 45 (range: 9-518) pmol/L11. The 99th percentile upper reference limit 
of pro-ENK in healthy subjects was 80 pmol/L11.  
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Renal mechanistic cohort (chronic heart failure) 
Patient selection and measurement procedure of renal hemodynamic parameters have been  
described elsewhere8, 9. In brief, 120 ambulatory patients with heart failure with left ventricular 
ejection fraction (LVEF) <45% on stable doses of ACE inhibitor or ARB for at least one month 
were included at University Medical Centre Groningen. All patients who consented to participate 
underwent GFR and effective renal plasma flow measurement using 125I-Iothalamate and 131I-
Hippuran. Renal blood flow (RBF) was calculated as effective renal plasma flow/1-haematocrit. 
GFR and RBF were expressed per body surface area. pro-ENK values were measured in 95 
available plasma samples. Serum cystatin C levels were measured by nephelometry. Urinary 
tubular markers including neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-
glucosaminide for N-acetyl-β-D-glucosaminidase (NAG), and Kidney Injury Molecule 1 (KIM-1) 
were also determined by ELISA as previously described9.  
 
Acute heart failure cohort  
We also measured pro-ENK in the PROTECT study cohort. The details of the design, results, 
and conclusions of this study have already been published10, 12, 13. In brief, 2,033 patients with 
acute heart failure with renal function impairment (estimated creatinine clearance between 20 to 
80 mL/min with Cockcroft–Gault formula) were included and randomized to rolofylline or 
placebo. The protocol of the PROTECT study was approved by the ethics committee at each 
participating center, and written informed consent was obtained from all participants. We 
measured pro-ENK in 1,589 patients at baseline (day 1) 1,465 patients at day 2, and 1,200 
patients at day 7 as samples were available. The following biomarkers were also evaluated at 
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baseline; albumin, blood urea nitrogen (BUN), creatinine, glucose, hemoglobin, potassium, 
sodium, total cholesterol, triglycerides, uric acid and white blood cell count were measured by 
ICON Laboratories, Farmingdale, New York. N-Terminal pro Brain Natriuretic Peptide (NT-
proBNP) was determined by screening using commercial assays available at study sites. NGAL 
and C-reactive protein were measured in available frozen plasma samples by Alere Inc., San 
Diego, CA, USA. NGAL was measured using sandwich enzyme-linked immunosorbent assays 
(ELISA) on a microtiter plate; C-reactive protein was measured using a competitive ELISA on a 
Luminex platform.  
We also evaluated the association between worsening renal function (WRF), pre-defined in 
PROTECT as a creatinine increase of ≥0.3 mg/dL from baseline (day 1) value or initiation of 
hemofiltration or dialysis at any time between day 1 to day 4.   
The prognostic value of pro-ENK was evaluated with 1,589 AHF patients with available Pro-
ENK value at baseline using three endpoints: all-cause mortality within 180 days, heart failure 
rehospitalization through 60 days, and death or cardiovascular or renal rehospitalization through 
day 60 days14.  
 
Statistical analysis 
In both cohorts, data are expressed as mean and standard deviation for normally distributed 
variables, and as median with interquartile range for non-normally distributed data. Categorical 
data are expressed as numbers and percentages. The relationship between baseline 
characteristics and tertiles of pro-ENK were compared by using one-way analysis of variance 
test, Kruskal-Wallis test, or chi-squared tests where appropriate. A post-hoc test for pairwise 
comparison was performed with Bonferrroni correction. When necessary, variables were 
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transformed for further analyzes. Stepwise multiple linear regression analysis was performed 
using backward elimination  with a P value <0.10 as the criterion for retention after including all 
variables with P value <0.10 in univariate analysis to identify factors independently associate to 
pro-ENK levels.  
In the acute heart failure cohort, univariate logistic regression was performed to evaluate 
predictability of pro-ENK for WRF. If pro-ENK was significant in univariate logistic regression, 
multivariable logistic regression was performed to adjust for baseline creatinine levels to 
evaluate additive predictability for WRF. The longitudinal trajectory of pro-ENK over time (day 1, 
day 2 and day 7) was assessed by using linear mixed effect models to account for within-
individual correlation of repeatedly measured values of pro-ENK. For this analysis, we excluded 
patients who died within 7 days. Identification of subjects was included as random effects, and 
time was modeled linearly. We used age, previous heart failure hospitalization, peripheral 
edema, systolic blood pressure, serum sodium, log blood urea nitrogen, log creatinine, and 
albumin as fixed effects as these were suggested as factors of prognostic predictive value in 
this cohort15. For prognostic analysis, we adjusted log pro-ENK by a model that was previously 
defined for this cohort, including age, previous heart failure hospitalization, peripheral edema, 
systolic blood pressure, sodium, log blood urea nitrogen, log creatinine and albumin.15. In this 
cohort, predictability of this model was confirmed to be similar to more complex models for 
outcome of all-cause mortality within 180 days, death or rehospitalization for any reason within 
30 days, and cardiovascular or renal rehospitalization within 30 days. We evaluated prognostic 
predict ability of pro-ENKN in three multivariable Cox models: adjusted for age and gender 
(Model 1), adjusted for age, gender, creatinine, and BUN (Model 2), and adjusted for the clinical 
model (Model 3). A two-tailed P value < 0.05 was considered statistically significant. Statistical 
analyses were performed using R version 3.1.2 (R Foundation for Statistical Computing, Vienna, 
Austria). ISBN 3-900051-07-0, URL http://www.R-project.org.  
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Results 
Renal mechanistic cohort 
Patient characteristics 
Baseline characteristics are shown in Table 1. The mean age was 60±12 years, 75 patients 
(79%) were male, and mean LVEF was 29±10%. The median value of pro-ENK was 62.2 (IQR: 
48.5 –92.5) pmol/L (Figure1), and 28 (29.5%) patients had pro-ENK levels above 99th percentile 
upper reference limit of pro-ENK in healthy subjects. Higher pro-ENK tertiles were associated 
with higher age, females, lower blood pressure, higher NYHA class, greater diuretics use and 
higher plasma NT-proBNP levels (all P<0.05).  
 
Correlation between renal markers and pro-ENK   
Supplemental Table 1 shows the result of univariate linear regression analysis between log pro-
ENK, renal markers and renal hemodynamic parameters. pro-ENK values were strongly and 
significantly associated with creatinine, BUN, Urinary Albumin Excretion, Cystatin C, GFR, and 
RBF but not with urinary tubular markers (NAG, NGAL, and KIM-1).  
 
Table 2 shows the result of multivariable linear regression analysis for pro-ENK. In the final 
model (R2=0.616), higher log pro-ENK levels were associated with lower GFR (standardized 
beta = -0.377) higher BUN, higher NT-proBNP, lower NYHA class, and lower systolic blood 
pressure.  
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Acute heart failure cohort 
Patient characteristics  
Baseline characteristics of the PROTECT AHF cohort according to pro-ENK tertiles are shown 
in Table 3. The mean age was 71±11 years, 1049 (66%) were male, and mean LVEF was 33±
13%. The median value of pro-ENK was 104.9 (IQR: 73.7 – 146.6) pmol/L (Figure 1), and 1092 
(68.7%) patients had pro-ENK levels above 99th percentile upper reference limit of pro-ENK in 
healthy subjects. At baseline, higher pro-ENK levels were associated with higher age, females, 
lower diastolic blood pressure, preserved LVEF (≥45%), history of diabetes, higher creatinine, 
higher BUN, and higher brain natriuretic peptide (BNP).  
 
Correlation between covariates and pro-ENK 
The result of univariate and multivariable linear regression analysis of pro-ENK is shown in 
Supplemental Table 2 and Table 2, respectively. Serum creatinine was the primary determinant 
of log pro-ENK among baseline variables (standardized beta = 0.422, P<0.001), and followed by 
females, higher age, higher BNP, and higher BUN in PROTECT acute heart failure cohort.  
 
Association between pro-ENK and WRF 
High pro-ENK values at baseline were associated with a higher incidence of worsening renal 
function (Table 4). In univariate logistic regression, log pro-ENK was significantly associated 
with worsening renal function (Odds ratio: 1.47, 95% CI: 1.18-1.84, P<0.001). However, the 
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significance was attenuated after adjustment for log creatinine (Odds ratio: 1.24, 95% CI: 0.95-
1.61, P=0.119). In a sensitivity analysis, log pro-ENK was not a significant predictor of WRF with 
other definitions (≥25% increase or ≥25% and ≥0.3 mg/dL increase in creatinine from baseline 
levels) even in a univariate logistic regression analysis (data not shown). 
 
Association of pro-ENK with prognosis 
Kaplan-Meier curves of each tertile for mortality through day 180 are shown in Figure 2. Higher 
tertiles of pro-ENK were associated with 180 days mortality (P<0.001). In Cox regression 
models, high log pro-ENK levels were significantly associated with all of the three outcomes; 
death through 180 days, heart failure rehospitalization through day 60, and death or 
cardiovascular or renal rehospitalization through day 60 in univariable Cox regression analysis, 
and even after adjustment for age and gender (Model 1). Log pro-ENK was a significant 
predictor only for endpoint of death through day 180 even after being adjusted by age, gender, 
creatinine, and BUN (Model 2). However, log pro-ENK lost its significance for all of outcomes 
after adjustment for the PROTECT prognostic model; including age, history of heart failure 
hospitalization, severity of peripheral edema, systolic blood pressure, serum sodium, BUN, 
creatinine, and Albumin (Model 3) (Table 4). There was no significant interaction between 
rolofylline treatment and prognostic predictive ability of pro-ENK for any of outcomes (all P for 
interaction >0.3).  
 
Serial changes in pro-ENK over time and prognosis 
We compared the trajectory of pro-ENK values at day 1, day 2, and day 7 and percent change 
from baseline to day 2 and day 7 between patients with and without death through 180 days 
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after excluding 29 patients who died within 7 days of admission (Figure 3). Baseline pro-ENK 
value was higher in patients who died compared with those who were alive. In the mixed effect 
model, there was no significant difference between patients who died or survived with regard to 
absolute or relative changes over time (P=0.760 and P=0.258, respectively). Similar results 
were obtained for the endpoints of heart failure rehospitalization through 60 days and death or 
cardiovascular or renal rehospitalization through day 60 (P>0.05 for all) (Supplemental Figure 1). 
We also evaluated the prognostic importance of percent change in pro-ENK from baseline (day 
1) to day 2 and from baseline to day 7 as a numeric variable, and neither showed independent 
prognostic information in multivariate Cox regression analysis (Supplemental Table 3). 
  
Discussion 
In acute and chronic heart failure, pro-ENK levels were higher in acute HF compared with 
chronic HF. Pro-ENK was clearly associated with renal blood flow and glomerular filtration rate 
but not with tubular function. In patients with heart failure, pro-ENK was associated with clinical 
outcome, but after adjustments for established prognostic predictors including preexisting renal 
markers, this association was lost. Therefore, pro-ENK seems to be a renal marker, but does 
not seem to have additive value on top of the established prognostic markers.   
 
Pro-ENK as a renal biomarker in patients with heart failure 
The endogenous opioid system is one of the most studied innate pain-relieving systems. In 
addition, the endogenous opioid system has also been suggested to have a negative effect on 
the cardiovascular system. Two observational studies suggested that activity of the endogenous 
opioid system was activated in patients with heart failure compared with healthy subjects16, 17. 
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Additionally, in an experimental dog model of congestive heart failure, delta-opioid receptor 
(OPR) was specified as a more relevant receptor subtype among several OPRs in terms of 
hemodynamic regulation18. In this study, a selective antagonist for delta-OPR increased aortic 
pressure, cardiac output, and blood flow to the myocardium and kidney. These results 
suggested that delta-OPR plays a main role in the opioid system as a cardiovascular modulator, 
and measuring activity of enkephalin - a specific peptide to delta-OPR - might be useful to 
evaluate the effect of the opioid system in patients with heart failure. Recently, pro-ENK was 
suggested as a stable and reliable surrogate marker of enkephalin and it became possible to 
evaluate enkephalin activity in vivo5.   
In the present study, we showed that levels of pro-ENK were relatively high in patients with both 
acute and chronic heart failure when pro-ENK value derived from normal subject was used as 
reference. Furthermore, both in the chronic and acute heart failure cohorts we found a 
consistent association between pro-ENK and several renal markers. Moreover, precise 
evaluation of renal function in the chronic heart failure cohort showed that pro-ENK levels were 
strongly associated with renal blood flow and glomerular filtration rate. These results are in 
agreement with the finding that delta-OPR was highly expressed in the kidney and inhibition of 
delta-OPR increased kidney blood flow in an experimental heart failure model4, 18. Moreover, 
pro-ENK was positively correlated with albuminuria in the chronic heart failure cohort. These 
findings show that pro-ENK is a novel renal marker. The pathophysiologic mechanism or rather 
determinants of pro-ENK including renal clearance has to be evaluated in future studies.   
We evaluated the association between pro-ENK and worsening renal function in acute heart 
failure, and found that pro-ENK was not a predictor of worsening renal function in patients with 
heart failure independent from serum creatinine. This is in line with a previous study that 
evaluated the association between pro-ENK values before surgery and acute kidney injury in 
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patients undergoing cardiac surgery. In this study, baseline pro-ENK values were strongly 
associated with baseline creatinine. Pro-ENK levels were also associated with acute kidney 
injury after surgery, but did not outweigh creatinine6. These and our results showed that the 
association between pro-ENK and worsening renal function can be attributed to the significant 
association with creatinine, and pro-ENK by itself provides limited additive information to 
creatinine in terms of changes in renal function.  
 
Prognostic information of pro-ENK in heart failure 
In our present analysis, pro-ENK was not an independent predictor of prognosis in acute heart 
failure cohort in spite of its association with renal function and severity of heart failure. This 
result suggests that pro-ENK provides limited additional prognostic information to preexisting 
prognostic markers of patients with heart failure including renal biomarkers.  
Our findings are inconsistent with previous two studies which investigated prognostic role of pro-
ENK in patients with myocardial infarction and non-symptomatic patients with heart failure, 
where higher pro-ENK levels were an independent predictor of a combined endpoint of death 
and adverse events even after adjustment for other prognostic factors7, 19. This discordance 
might be due to a difference in study population. Another possible explanation is an association 
between pro-ENK and BUN. In the aforementioned study of myocardial infarction patients, pro-
ENK was an independent predictor of mortality after being adjustment for the Global Registry of 
Acute Coronary Events (GRACE) model20, and pro-ENK showed incremental prognostic 
information. However, the GRACE model does not include information about BUN, and as a 
consequence, it is unclear whether pro-ENK would have been a significant predictor of events if 
the model would have been adjusted for BUN. Recent studies showed that BUN was an 
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independent predictor of mortality also in acute myocardial infarction patients even after being 
adjusted by eGFR21, 22 and indeed pro-ENK was significantly and strongly correlated with BUN 
in our cohort. Recently, Arbit et al. investigated the role of pro-ENK in patients referred to 
echocardiography and categorized into stage A or B HF (symptomatic HF patients were 
excluded). Pro-ENK correlated with serum creatinine and eGFR, and was an independent 
predictor of worse prognosis after adjustment for some prognostic factors. However, in contrast 
to the present study, these patients were asymptomatic and were not adjusted for BUN, which 
was a strong confounder in our study19. The relationship between pro-ENK and BUN might be 
an explanation why pro-ENK was an independent prognostic predictor in these previous studies 
but not in our cohort.  
 
Limitations 
This study has important limitations due to its retrospective character. In the chronic HF cohort, 
number of patients were limited so that prognostic predictability of pro-ENK in a chronic heart 
failure population remains to be elucidated. In the acute heart failure cohort, only patients with 
heart failure with mild renal impairment were included by study design. Echocardiographic 
measurements were obtained in only less than half of all patients. Moreover, pro-ENK levels 
were not available in some patient of both cohorts due to availability of plasma, which could 
have influenced the results despite the fact that there was no significant difference in event rate 
for any endpoints between patients with available samples and those without (all P value >0.5).   
 
Conclusion   
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Pro-ENK levels were higher in acute heart failure when it compared with chronic heart failure. 
Pro-ENK levels were strongly associated with glomerular function and renal blood flow, but not 
with tubular damage. Pro-ENK has limited additive prognostic predictive information on top of 
existing renal markers in this cohort of acute heart failure.  
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Figure legends 
Figure 1. Baseline pro-ENK values in renal mechanistic cohort and acute heart failure 
cohort 
 
The box represent interquartile ranges, the horizontal line in each box represents the median, 
and the whiskers show the 10-90 percentile range. 
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Figure 2. Kaplan-Meier curves of each tertile of pro-ENK in acute heart failure cohort  
 
Survival curves of each pro-ENK tertile in acute heart failure cohort. 
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Figure 3. Changes in pro-ENK in patients with and without death through 180 days 
 
Median value is expressed as open circle and interquartile range is expressed as error bars.
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Table 1. Baseline characteristics and relationship between tertiles of pro-ENK in renal mechanistic cohort 
Variables 
All cohort   Terile 1 Tertile 2 Tertile 3 
P value 
(n=95)   (n=32) (n=31) (n=32) 
pro-ENK (median, [min-max], 
pmol/mL) 
62.2 [29.3-306.6]   45.7 [29.3-53.2] 62.2 [53.5-75.5] 102.5 [76.1-306.6] 
Age (yrs) 60±12 
 
 56±11†  61±11  63±12 0.034 
Male (%) 75 (79)    27 (84)  28 (90)‡  20 (63)  0.017 
Body surface area (m2) 2.0±0.2   2.1±0.2† 2.0±0.2 1.9±0.2 0.003 
Systolic blood pressure (mmHg) 120±21 
 
130 ±20† 121 ±19‡ 109 ±20 <0.001 
Diastolic blood pressure (mmHg)  69±12    75 ±10†  72 ±11‡  61 ±11 <0.001 
Heart rate (bpm)  65±13 
 
 64 ±11  65 ±15  67 ±12 0.815 
Ischemic etiology (%) 52 (55)   15 (47)  20 (65)  17 (53)  0.363 
Diabetes (%) 13 (14) 
 
 6 (19)   2 (7)   5 (16)  0.338 
Smoking current or Ex (%) 47 (49)   13 (43) 19 (63) 15 (52) 0.297 
NYHA III or IV (%) 34 (36) 
 
 4 (13)†  11 (36)  19 (59)  <0.001 
LVEF (%)  29±10    30±9†  28±10  27±10 0.441 
Medication 
      
ACE-I (%) 78 (82)   27 (84)  27 (87)  24 (75)  0.419 
ARB (%) 18 (19) 
 
 5 (16)   5 (16)   8 (25)  0.562 
Beta blocker (%) 80 (84)   27 (84)  26 (84)  27 (84)  0.998 
Mineralocorticoid Receptor Antagonist 
(%) 
28 (30) 
 
 8 (25)   5 (16)‡  15 (47)  0.022 
Diuretics (%) 63 (66) 
 
18 (56) 18 (58) 27 (84) 0.029 
Hemoglobin (g/dL)  14.0±1.4     14.3±1.1†   14.0±1.0‡   13.2±1.6 0.001 
Hematocrit (%)  42±4 
 
  42±3†   43±3‡   39±5 0.001 
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NT-ProBNP (ng/L)  
854.0  
(287.8-1911.5) 
  
370.4†  
(204.6-829.6) 
431.1‡  
(218.3-1210.0) 
1973.0  
(1186.3-3214.0) 
<0.001 
Renal function 
      
Creatinine (mg/dL) 1.2 (1.0-1.4)    1.0 (1.0-1.2)† 1.1 (1.1-1.3)‡ 1.5 (1.2-1.8) <0.001 
BUN (mg/dL)  20.4 (16.7-29.1) 
 
16.7 (14.2-19.2)*† 19.9 (18.4-22.4)‡ 33.2 (24.7-41.5) <0.001 
Cystatin C (mg/L) 0.82 (0.70-1.02)   0.69 (0.49-1.78)*† 0.81 (0.59-1.12)‡ 1.19 (0.64-2.09) <0.001 
GFR (mL/min/1.73m2) 72.4±27.9 
 
 92.2±23.4*†  77.2±15.2‡  47.2±22.5 <0.001 
RBF (mL/min/1.73m2) 450.1±162.2   563.3±145.2*† 470.7±94.4‡ 307.5±138.4 <0.001 
FF (%) 28.0 (25.0-29.9) 
 
 28.4 (25.8-30.1)  28.3 (26.6-29.2)   26.5 (20.4-29.6) 0.122 
Urinary KIM-1 (ng/gCr) 
354.6   386.9 276.5 305.2 
0.909 
(218.4-604.7)   (219.7-536.7) (207.5-630.1) (220.3-549.2) 
Urinary NAG (U/gCr) 12.9 (6.5-16.9) 
 
  13.3 (6.0-17.2)   10.3 (6.5-12.8)‡   15.0 (13.1-19.6) 0.035 
Urinary NGAL (μg/gCr) 
177.6 (61.1-
341.8) 
  
152.8 (52.7-
314.0) 
187.7 (79.9-
329.4) 
  153.2 (57.5-
366.5) 
0.563 
Urinary Creatinine (mmol/L)  6.2 (4.6-8.4) 
 
  7.4 (5.1-9.4)   6.3 (4.6-8.0)    6.1 (4.6-7.7) 0.391 
Urinary Albumin (mg/L)  5.4 (3.3-11.8)     4.8 (2.2-8.9)†   4.8 (3.2-7.0)‡   15.0 (4.6-41.0) 0.003 
† P < 0.05, Tertile 1 vs Tertile 2 
‡ P < 0.05, Tertile 1 vs Tertile 3 
§ P < 0.05, Tertile 2 vs Tertile 3  
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; GFR, glomerular 
filtration rate; KIM-1, kidney injury molecule 1; LVEF, left ventricular ejection fraction; NAG, N-acetyl-ϐ-D-glucosaminidase; NGAL, 
neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; 
pro-ENK , proenkephalin
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Table 2. Multivariable linear regression for pro-ENK in renal mechanistic and acute heart failure cohort 
Multivariate linear regression for Log PENK 
Variables Standardized Beta  t  P value 
Renal mechanistic cohort (Adjusted R2=0.616) 
GFR per BSA -0.377 -3.189 0.002 
Log BUN 0.321 2.996 0.004 
Log NT-proBNP 0.284 3.092 0.003 
NYHA III or IV -0.245 -2.617 0.010  
Systolic blood pressure -0.197 -2.845 0.005 
Acute heart failure cohort (Adjusted R2=0.469) 
Creatinine 0.445 14.30  <0.001 
Male -0.21 -9.647 <0.001 
Age 0.163 7.583 <0.001 
BNP 0.147 6.899 <0.001 
BUN 0.119 3.819 <0.001 
Hemoglobin -0.113 -5.273 <0.001 
BMI -0.097 -4.507 <0.001 
Glucose  -0.085 -4.167 <0.001 
Potassium 0.077 3.687 0.002 
Uric acid 0.056 2.442 0.015 
BMI, body mass index; BNP; brain natriuretic peptide; BUN, blood urea nitrogen; GFR, glomerular filtration rate; NT-proBNP, N-
terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; pro-ENK, proenkephalin 
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Table 3. Baseline characteristics according to tertiles of pro-ENK in acute heart failure (PROTECT) cohort 
Variables 
All cohort   Tertile 1 Tertile 2 Tertile 3 
P value (n=1589)   (n=530) (n=529) (n=530) 
pro-ENK (median, [min-max]) 104.9 [6.5-511.7]   64.4 [6.5-82.9] 104.9 [83.0-131.8] 173.5 [131.9-511.7] 
Age (years) 71±11   67±11†‡  71±11§  74±10 <0.001 
Male (%) 1049 (66)   379 (72) ‡ 343 (65)  327 (62)  0.003 
Systolic blood pressure (mmHg) 125±17  126±17 123±18 125±18 0.067 
Diastolic blood pressure (mmHg) 74±12    76±11†‡  73±12  72±12 <0.001 
Pulse rate (bpm) 80±16   82±15†  80±15  78±16 0.001 
Assigned to Rolofylline (%) 1065 (67)  352 (66)  354 (67)  359 (68)  0.899 
LVEF (%) 32±13    31±13‡  31±13§  35±13 0.002 
HFpEF (LVEF ≥45%) (%)* 152 (20)   35 (15)‡   49 (19)   68 (26)  0.011 
Prior medication (%)             
ACE-I  993 (63)  352 (66) ‡ 333 (63)  308 (58)  0.019 
ARB  241 (15)    60 (11)†‡   91 (17)   90 (17)  0.01 
Beta blocker  1196 (75)  394 (74)  404 (77)  398 (75)  0.707 
Calcium channel blocker  225 (14)    59 (11)‡   69 (13)   97 (18)  0.002 
Aldosterone inhibitor  718 (45)  263 (50)‡  240 (46)  215 (41)  0.012 
Digoxin  457 (29)   177 (33)‡  171 (32)§  109 (21)  <0.001 
Past history (%)       
Hypertension  1272 (80)   414 (78)  419 (79)  439 (83)  0.132 
Diabetes  733 (46)  234 (44)  233 (44)  266 (50)  0.072 
Smoking  310 (20)   118 (22)  103 (20)   89 (17)  0.079 
Heart failure hospitalization  782 (49)  234 (44)†  280 (53)  268 (51)  0.013 
Atrial fibrillation  860 (54)   266 (51)  303 (57)  291 (55)  0.078 
Worsening renal function (%)  371 (23)   99 (19)‡  115 (22)§  157 (30)  <0.001 
Biomarkers             
WBC count (x109/L) 7.42 (6.04-9.22)      7.43 (6.25-9.05)     7.40 (6.13-9.15)     7.42 (5.84-9.40) 0.929 
Hemoglobin (g/dL) 12.5 (11.2-13.8)      13.1 (11.9-14.4)†‡    12.7 (11.4-13.8)§    11.7 (10.6-12.9) <0.001 
Total cholesterol (mg/dL) 141 (117-173)    149 (123-178)†‡   139 (116-168)   136 (114-167) 0.001 
Triglycerides (mgl/dL) 88 (65-122)      95 (72-126)†‡    82 (61-120)    84 (63-120) <0.001 
Albumin (mgl/dL) 3.8 (3.6-4.1)      3.9 (3.6-4.2)‡     3.9 (3.6-4.1)§     3.8 (3.5-4.1) <0.001 
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BUN (mg/dL) 30 (22-41)      22 (18-28)†‡    29 (23-38)§    42 (32-56) <0.001 
Creatinine (mg/dL) 1.4 (1.1-1.8)      1.1 (0.9-1.3)†‡     1.4 (1.2-1.6)§     1.8 (1.5-2.3) <0.001 
NGAL (ng/mL) 82.4 (52.8-135.1)   56.6 (39.8-82.9)†‡ 75.8 (53.9-112.5)§ 132.8 (87.8-198.8) <0.001 
Sodium (mEq/L) 140 (137-142)    140 (137-143)‡   140 (137-142)   139 (137-142) 0.013 
Potassium (mEq/L) 4.2 (3.9-4.6)       4.1 (3.8-4.5)‡     4.2 (3.8-4.6)§     4.3 (3.9-4.8) <0.001 
Glucose (mg/dL) 128 (103-164)    133 (106-175)†‡   124 (101-162)   126 (101-160) 0.008 
Uric acid (mg/dL) 8.8 (7.2-10.6)       7.9 (6.6-9.5)†‡     8.9 (7.3-10.6)§     9.6 (7.9-11.6) <0.001 
BNP (pg/mL) 449.2  319.3†‡ 510.9 542 <0.001 (255.9-801.5)  (201.6-556.6) (277.8-854.9) (293.9-968.9) 
C-reactive protein (ng/mL) 
13844   13683 13307 14707 
0.303 
(7271-27939)   (6978-27339) (6956-27048) (8037-29315) 
* P < 0.05, Tertile 1 vs Tertile 2 
† P < 0.05, Tertile 1 vs Tertile 3 
‡ P < 0.05, Tertile 2 vs Tertile 3  
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic 
peptide; BUN, blood urea nitrogen; HFpEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction; 
NGAL, Neutrophil Gelatinase-Associated Lipocalin; pro-ENK , proenkephalin; WBC, white blood cell 
*LVEF data was only available in 763 (48.0%) patients.  
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Table 4. Cox regression for outcomes in acute heart failure cohort 
Outcomes Number of Events (%) 
Univariable   Model 1 (adjusted by age and gender)   
Model 2 (adjusted by 
Model 1 + log Creatinine 
and log BUN) 
  Model 3 (adjusted by clinical model*) 
HR  95%CI P value   HR  95%CI P value   HR  95%CI P value   HR  95%CI P value 
Death through Day 
180 278 (17.5) 2.11 1.68-2.67 <0.001   2.02 1.59-2.57 <0.001   1.41 1.02-1.96 0.039   1.23 0.91-1.66 0.178 
Heart Failure 
Rehospitalization 
through Day 60 
227 (14.3) 1.43 1.12-1.84 0.005  1.53 1.18-1.97 0.001  1.01 0.72-1.38 0.933  1.01 0.74-1.36 0.977 
Death or 
Cardiovascular or 
Renal 
Rehospitalization 
through Day 60  
457 (28.8) 1.58 1.33-1.89 <0.001   1.63 1.36-1.96 <0.001   1.18 0.94-1.50 0.162    1.15 0.91-1.45 0.257  
BUN, blood urea nitrogen 
* Adjusted for age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, sodium, log blood urea nitrogen, log creatinine 
and albumin 
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